CD&R Nears Sanofi OTC Deal After Signing With Government

Bpifrance is expected to take a small stake in the OTC unit
Sanofi said it will upgrade its 2024 earnings guidance

The headquarters of Sanofi SA in Paris, France.
Photographer: Nathan Laine/Bloomberg

Provide news feedback or report an error

Confidential tip?

Send a tip to our reporters

Site feedback:

Take our Survey

By Pamela Barbaglia, Ashleigh Furlong, and Francois de Beaupuy

October 20, 2024 at 5:56 PM UTC

Updated on

October 21, 2024 at 8:36 AM UTC

This article is for subscribers only.

Sanofi entered a fresh round of exclusive negotiations to sell control of its consumer health unit to Clayton Dubilier & Rice after France secured commitments on local employment and investment and agreed to take a minority stake.

The talks would see Sanofi transfer a 50% controlling share of its Opella business to the US buyout firm, according to a statement Monday, giving it an enterprise value of about €16 billion ($17.4 billion).